<DOC>
	<DOCNO>NCT02776423</DOCNO>
	<brief_summary>Transurethral injection use polyacrylamide hydrogel ( Bulkamid® , Contura A/S , Denmark ) establish treatment stress urinary incontinence . The rate woman report improvement cure Bulkamid injection stress urinary incontinence range 64-77 % low morbidity . However , indication use unclear . Although transurethral polyacrylamide hydrogel injection inferior midurethral sling regard expect cure rate , procedure associate low rate adverse event general serious adverse event particular . As , may important alternative patient surgery consider safe option either co-morbidity complicate incontinence . The investigator perform prospective study determine effect transurethral polyacrylamide hydrogel injection patient consider ineligible midurethral sling surgery .</brief_summary>
	<brief_title>Polyacrylamide Injection Patients Ineligible Surgery</brief_title>
	<detailed_description>In prospective observational study investigator include female patient receive treatment transurethral polyacrylamide hydrogel injection ( Bulkamid® ) . Patients consider ineligible surgery base significant co-morbidity , one previously fail invasive treatment , complex urinary incontinence , previous pelvic radiation therapy . At baseline visit patient underwent routine gynecological exam include pelvic ultrasonography . Patients complete validated questionnaire baseline visit follow-up evaluation subjective treatment success . At baseline , woman ask self-report concomitant diseases health condition note patient record together standard gynecological , urological general health history . Follow-up visit schedule 2 6 month first injection time second injection administer patient ' discretion .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<criteria>Women stress urinary incontinence consider ineligible surgery base significant comorbidity , one previously fail invasive treatment , complex urinary incontinence , previous pelvic radiation therapy . Patients want treatment participate study followup Below 18 year age</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>